SecBot SecBot
8-K ·Filed Aug 31, 2026

UTMD

UTAH MEDICAL PRODUCTS INC
BULLISH
Impact 5/10
Horizonweeks Processed2mo ago SEC0001096906-26-001326
8-K context-dependent: Items 7.01
Actionable Insight ▲ Bullish

The acquisition is a small bolt-on that should modestly boost revenue and margins. No debt or equity issuance was used. Monitor the Q3 2026 10-Q (due by Oct 15) for integration details and margin impact. The deal does not change UTMD's core strategy but provides a stable, accretive revenue stream.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$71.13
T+0 close · Aug 31, 2026 · via day close
Latest settled
+5.37%
T+20 · $74.95 · next T+60 in 7d
Vs SPY
+5.56%
α at T+20
Latest observation
+3.40%
T+52 · FF3 residual α
  1. T+0 · Aug 31 $71.13entry
  2. T+1 · 3mo ago +0.89%α +1.57% · $71.76
  3. T+5 · 2mo ago −2.77%α −2.63% · $69.16
  4. T+20 · 7w ago +5.37%α +5.56% · $74.95
  5. T+54 · todayOpen
  6. T+60 · in 7d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

UTMD's UK subsidiary Femcare Ltd acquired all shares of Orion Medical Supplies Ltd for 3.6 million in cash. Orion is a niche harm-reduction device assembler/distributor; the deal is expected to add ~$6M to UTMD's annual sales and be accretive by leveraging existing Femcare infrastructure. The acquisition is small relative to UTMD's $232M market cap but uses cash reserves with no dilution.

Key Facts

  • Purchase price of 3.6 million paid from cash reserves
  • Expected to add about $6 million to UTMD's consolidated annual sales
  • Orion is a UK-based assembler/distributor of harm reduction medical devices
  • Acquisition is not synergistic from a medical use perspective but is accretive via overhead leverage
  • Orion's operations will move into Femcare's existing Romsey facilities after a transition period

Financial Impact

Adds ~$6M to annual revenue (approx. 10-12% of current sales) for a cash purchase price of 3.6M; accretive due to overhead dilution

revenueoverhead expenses

Risk Factors

  • Integration risk as Orion's harm reduction products are not synergistic with UTMD's existing device portfolio
  • Potential distraction from core business during facility move and transition
  • Limited growth upside given the niche market and retiring founders

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001096906-26-001326
Document: utmd_ex99z1.htm0001096906-26-001326
Document: 0001096906-26-001326-index-headers.html0001096906-26-001326
Document: 0001096906-26-001326-index.html0001096906-26-001326
Document: 0001096906-26-001326.txt0001096906-26-001326

US Market Status

Market Closed · Opens in 6h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 31, 2026